PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") dated September 3, 2025 with its subsidiary, BioGene Therapeutics Inc. ("BioGene"), pursuant to which PreveCeutical intends to spin-out 12,000,000 common shares of BioGene (the "BioGene Spinout
Biotechnology, Pharmaceuticals, Health
2025-09-04 4:00 PM EDT | PreveCeutical Medical Inc.
Hemostemix's VesCell.Health Launched in Florida
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, today announces it la
Biotechnology, Pharmaceuticals, Health
2025-09-04 9:47 AM EDT | Hemostemix Inc.
Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27th Annual Global Investment Conference. Presentation Details
Biotechnology, Pharmaceuticals
2025-09-04 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, celebrated the 17+ ye
Biotechnology, Pharmaceuticals, Health
2025-09-03 8:47 AM EDT | Hemostemix Inc.
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-03 7:45 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP psychedelic medicines, is pleased to announce the commercial launch of its natural psilocybin capsules in Australia, which are now being prescribed to patients with Treatment-Resistant Depression ("TRD") under the Authorised Prescriber Scheme. The initial shipment of 1,000 psilocybin capsules, each conta
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-03 7:30 AM EDT | Optimi Health Corp.
TempraMed Closes Oversubscribed C$7.4M Financing and Advances Toward Go Public Listing
Sammamish, Washington--(Newsfile Corp. - September 3, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator redefining how temperature-sensitive medications are stored, managed and protected, is pleased to announce significant corporate and capital markets milestones, including the successful close of an oversubscribed C$7.4 million private placement financing and strong progress toward its public listing on the Canadian Securities Exchange (CSE), expected mid-
Technology, Biotechnology, Pharmaceuticals, Health
2025-09-03 7:00 AM EDT | TempraMed Technologies Ltd
BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET
Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time. CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update
Biotechnology, Pharmaceuticals, Health
2025-09-02 8:30 AM EDT | BioHarvest Sciences Inc.
Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader in intelligent automation platforms for accelerating chemical process development, is pleased to announce the appointment of Vaso Vlachos as Chief Operating Officer (COO), effective immediately. Ms. Vlachos is a proven leader with over 20 years of experience managing automation and an
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-09-02 8:00 AM EDT | Telescope Innovations Corp.
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately. Dr. Phinney will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursue
Biotechnology, Pharmaceuticals, Health
2025-09-02 3:15 AM EDT | Defence Therapeutics Inc.
Theralase(R) Extends Warrants
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,840,000 share purchase warrants ("Warrants")
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-08-29 4:30 PM EDT | Theralase Technologies Inc.
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that, further to its News Release of June 25, 2025, July 8, 2025 and August 5, 2025, it has rescheduled its annual general and special meeting (the "Meeting") from September 29, 2025 to October 10, 2025 due to the necessity to comply with the various requirements in connection with the proposed plan of
Biotechnology, Pharmaceuticals, Health
2025-08-28 6:00 PM EDT | PreveCeutical Medical Inc.
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
Calgary, Alberta--(Newsfile Corp. - August 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida's SB 1768, announces it has organized patient financi
Biotechnology, Pharmaceuticals, Health
2025-08-28 2:52 PM EDT | Hemostemix Inc.
Nextleaf Reports Third Quarter FY25 Results Including Fourth Consecutive Profitable Quarter
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor, is pleased to announce its financial results for the third quarter of fiscal year 2025, ended June 30, 2025. The Company reported gross revenue of $3,769,797, net revenue of $2,912,572 and gross profit of $1,107,593. This marks the Company's four
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-08-28 9:00 AM EDT | Nextleaf Solutions Ltd.
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, today announced the advancement of its ketamine transdermal patch as a next-generation, non-opioid pain relief solution, building on the recent FDA approval of its IV ketamine product (KETARx™). "With KETARx™ now FDA-approved, our next
Biotechnology, Pharmaceuticals
2025-08-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Theralase(R) Releases 2Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 2Q2025 financial statements ("Financial Statements"). Theralase® will be host
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-08-26 4:30 PM EDT | Theralase Technologies Inc.
Hemostemix's Boots on the Ground in Florida
Calgary, Alberta--(Newsfile Corp. - August 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida's SB 1768, announces the launch of its face-to-face s
Biotechnology, Pharmaceuticals, Health
2025-08-26 9:12 AM EDT | Hemostemix Inc.
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gains Ongoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory discussions, including seeking alignment with FDA on potential expedited approv
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-26 7:30 AM EDT | NervGen Pharma Corp.
Defence Therapeutics Announces Debenture Units Financing
Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of up to $1,200,000 (the "Offering"). Each Unit will consist of (i) one $1,000 principal amount of
Biotechnology, Pharmaceuticals, Health
2025-08-22 8:30 PM EDT | Defence Therapeutics Inc.
NuGen Medical Devices Announces New Needle-Free Injection System Featuring Internal Cartridge Technology
Toronto, Ontario--(Newsfile Corp. - August 21, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is pleased to announce research and development of a next-generation needle-free injection system, in drug delivery technology. This innovation, protected under international patent WO2021206553 (granted in the EU and China; pending in Canada and the US), introduces a cartridge-based solut
Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-21 5:15 PM EDT | NuGen Medical Devices Inc.